Last reviewed · How we verify
NCT05770869
mHealth ALIBIRD: A Digital Health Care Model
NA trial testing ALIBIRD mHealth platform in Thoracic Neoplasms in 20 participants. Completed in 28 October 2022.
28 October 2022
Quick facts
| Lead sponsor | Fundación Investigación E Innovación Biomédica Hospital Universitario Infanta Sofia-Henares |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | other |
| Enrollment | 20 |
| Start date | 5 November 2021 |
| Primary completion | 28 October 2022 |
| Estimated completion | 28 October 2022 |
| Sites | 1 location across Spain |
Drugs / interventions tested
- ALIBIRD mHealth platform
Conditions studied
- Thoracic Neoplasms — all drugs for Thoracic Neoplasms →
Sponsor
Fundación Investigación E Innovación Biomédica Hospital Universitario Infanta Sofia-Henares
Who can join
Adults 18 to 80, any sex, with Thoracic Neoplasms. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this pilot study was to evaluate the feasibility and acceptability of the ALIBIRD platform, a new mobile health (mHealth) application prototype design for personalized and remote support on the follow-up of cancer patients. The ALIBIRD platform is a mHealth intervention that tracks PROs, improving symptom control and allowing real-time feedback, and provides personalized recommendations and educational content, promoting empowerment and encourage healthy lifestyle behaviors in patients with thoracic neoplasms in active treatment.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05770869
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Thoracic Neoplasms
Currently open trials in the same condition.
- NCT07159659 — Post-operative Medium Chain Triglyceride Diet May Reduce Hospital Stay Following Lung Resection · NA · recruiting
- NCT07242547 — Study of Tarlatamab as Maintenance Treatment After Chemo-radiotherapy for Limited Stage SCLC Patients · Phase 2 · recruiting
- NCT06917573 — PALACE: Cemiplimab Trial According to ctDNA Levels · Phase 2 · recruiting
- NCT06758700 — Post-line Treatment With Teniposide for c-Myc-driven Extensive-stage Small Cell Lung Cancer · Phase 2 · recruiting
- NCT06494241 — Small/Middle Tier Cities and County Lung Cancer Quality Improvement Project (QIP) Study · active not recruiting
Other Fundación Investigación E Innovación Biomédica Hospital Universitario Infanta Sofia-Henares trials
Trials by the same sponsor.
- NCT05080920 — Rosmalip® for Cancer Infections Prevention · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05770869 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fundación Investigación E Innovación Biomédica Hospital Universitario Infanta Sofia-Henares
- Last refreshed: 18 October 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05770869.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing